YONGIN, South Korea, May 7, 2024
/PRNewswire/ -- GC Genome Corporation, a leading diagnostics
company, today announced that it will present the new clinical data
of its AI-based liquid biopsy platform on colorectal cancer
detection at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago, May
31–June 4. This research was conducted through a collaborative
effort with Genece Health Inc., a strategic partner based in
San Diego.
Poster Presentation Details:
Title: Non-invasive colorectal cancer detection using
multimodal deep learning ensemble classifier.
- Date and Time: Saturday, June 1,
2024 9:00 AM - 12:00 PM
CDT
- Format: Poster Presentation
- Session Title: Developmental Therapeutics—Molecularly Targeted
Agents and Tumor Biology
- Poster Board Number: 211
- Abstract Number: 3066
[About GC Genome]
GC Genome is a leading diagnostics company that aims to connect
the care and cure to the world by offering genetic diagnosis
services for Oncology, Pre&Neonatal, Rare Diseases, and Health
Check-ups and suggesting personalized treatment for longer and
healthier lives. Established in 2013 as a GC company, GC Genome
operates a CAP-accredited laboratory and places the utmost emphasis
on R&D. With steadfast partnerships established worldwide, GC
Genome has shown impressive growth momentum, continually expanding
our testing capacities.
[About Genece Health]
Genece leverages a proprietary liquid biopsy and deep-learning AI
technology for early cancer detection. The Company was founded in
2022 through a strategic partnership with GC Genome, the genomics
arm of GC Corporation, a leading life sciences company in
South Korea. Genece focuses on the
acute need for targeted screening and detection tools to support
decision-making when a mass or lump is detected through imaging,
empowering physicians to make informed decisions and improve care.
The Company's initial applications include high-mortality and
women's health cancers.
Investor/Media Contact
GC Corp. Contacts (Media)
Sohee Kim
shkim20@gccorp.com
Yelin Jun
yelin@gccorp.com
Rachel Kim
rachel.kim@gccorp.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/gc-genome-to-present-new-clinical-data-on-colorectal-cancer-detection-at-the-asco-annual-meeting-2024-302137660.html
SOURCE GC Genome